Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
TapImmune
Biotech
TapImmune to merge with Baylor adoptive T-cell startup Marker
The agreement will give TapImmune control of adoptive T-cell therapies designed to provide more durable responses than CAR-Ts.
Nick Paul Taylor
May 15, 2018 9:50am
Chutes & Ladders—Allergan’s finance overseer to retire
Sep 29, 2017 9:20am
Chutes & Ladders—Celgene poaches top Merck R&D exec Plenge
May 4, 2017 4:02pm
AstraZeneca to trial a new cancer vaccine with its PD-L1 drug
Apr 22, 2016 10:16am
